Cargando…

Anti-Amyloid-β-Mediated Positron Emission Tomography Imaging in Alzheimer's Disease Mouse Brains

Antibody-mediated imaging of amyloid β (Aβ) in Alzheimer's disease (AD) offers a promising strategy to detect and monitor specific Aβ species, such as oligomers, that have important pathological and therapeutic relevance. The major current limitation of antibodies as a diagnostic and imaging de...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLean, Daniel, Cooke, Michael J., Wang, Yuanfei, Green, David, Fraser, Paul E., George-Hyslop, Peter St, Shoichet, Molly S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528731/ https://www.ncbi.nlm.nih.gov/pubmed/23284831 http://dx.doi.org/10.1371/journal.pone.0051958

Ejemplares similares

Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
por: Maschio, Cinzia, et al.
Publicado: (2022)

Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Thal, Dietmar Rudolf, et al.
Publicado: (2019)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Thal, Dietmar Rudolf, et al.
Publicado: (2020)

Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer’s Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography
por: Willuweit, Antje, et al.
Publicado: (2021)

Statistical Parametric Mapping in Amyloid Positron Emission Tomography
por: Smith, Natasha M., et al.
Publicado: (2022)

Detection of amyloid in Alzheimer’s disease with positron emission tomography using [(11)C]AZD2184
por: Nyberg, Svante, et al.
Publicado: (2009)

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease
por: Tian, Mei, et al.
Publicado: (2022)

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
por: Sala, Arianna, et al.
Publicado: (2020)

Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan
por: Tateno, Amane, et al.
Publicado: (2017)

Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity
por: Chun, Min Young, et al.
Publicado: (2023)

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
por: Grau-Rivera, Oriol, et al.
Publicado: (2021)

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2016)

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
por: Costoya-Sánchez, Alejandro, et al.
Publicado: (2023)

Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease
por: Lin, Szu-Ying, et al.
Publicado: (2019)

Regional Associations of Cortical Superficial Siderosis and β-Amyloid-Positron-Emission-Tomography Positivity in Patients With Cerebral Amyloid Angiopathy
por: Finze, Anika, et al.
Publicado: (2022)

Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography
por: Tripathi, Shailendra Mohan, et al.
Publicado: (2021)

Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
por: Yamashita, Kazuto, et al.
Publicado: (2022)

Amyloid deposition in semantic dementia: a positron emission tomography study
por: Brown, Eric E., et al.
Publicado: (2016)

Semiquantitative Approach to Amyloid Positron Emission Tomography Interpretation in Clinical Practice
por: Franceschi, Ana M., et al.
Publicado: (2022)

Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2015)

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
por: Palmqvist, Sebastian, et al.
Publicado: (2016)

Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update
por: Farid, Karim, et al.
Publicado: (2017)

Positron emission tomography
Publicado: (1995)

Positron Emission Tomography
por: Piepmeier, Joseph M.
Publicado: (1986)

Positron emission tomography
por: Paans, A M J
Publicado: (2006)

Cerebrospinal Fluid Levels of β-Amyloid 40 and β-Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients
por: Kim, Hyun Jae, et al.
Publicado: (2019)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations
por: Witte, Michael M., et al.
Publicado: (2015)

β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns
por: Jiang, Chenyang, et al.
Publicado: (2022)

Imaging mouse models of breast cancer with positron emission tomography
por: Cherry, S, et al.
Publicado: (2003)

Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer’s Sheds Light on Clinical Trial Exclusion Criteria
por: Major, Catherine K, et al.
Publicado: (2021)

A Single Baseline Amyloid Positron Emission Tomography Could Be Sufficient for Predicting Alzheimer’s Disease Conversion in Mild Cognitive Impairment
por: Choo, IL Han, et al.
Publicado: (2022)

Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
por: Zimmer, Eduardo Rigon, et al.
Publicado: (2014)

Imaging Brain Metabolism and Pathology in Alzheimer’s Disease with Positron Emission Tomography
por: Shokouhi, S, et al.
Publicado: (2014)

Positron emission tomography and X-ray computed tomography: tools for mouse phenotyping?
por: Cherry, SR
Publicado: (2003)

Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology
por: Gordon, Brian A., et al.
Publicado: (2018)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation
por: Price, Julie C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hatob3obgroqkkq9cmo7ksepk7